{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Stroke. Safety. Strategy: The Factor XIa Revolution \ud83d\ude80\ud83e\udde0","description":"&amp;nbsp; A quiet shift, yet a profound one. \ud83e\udde0 &amp;nbsp; The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding\u2014a long-sought balance in antithrombotic therapy. &amp;nbsp; For decades, we traded efficacy for safety. Now, we may finally have both. \u2696\ufe0f &amp;nbsp; The implications extend beyond stroke\u2014to a broader rethinking of thrombosis itself: can we uncouple clot from bleed? &amp;nbsp; This study suggests we can. &amp;nbsp; #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation #PrecisionMedicine ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40893510\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/200853595"}